TrialCancer science2022

Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).

Yutaka Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.